Our study suggests that cryo–thermal therapy combined with targeting CCL5 can desirably reverse immunosuppression and elicit stronger host anti-tumor immunity, leading to improved cryo–thermal therapeutic efficacy against poorly immunogenic breast cancer. The gene discussed is CCL5; the disease is neoplasm.